Physiologically based modeling of the inhalation kinetics of styrene in humans using a Bayesian population approach

Toxicology and Applied Pharmacology

Volumn 179, Issue 1, 2002, Pages 35-49

  Jonsson, Fredrik ^a   Johanson, Gunnar ^a,b  

^a NATIONAL INSTITUTE FOR WORKING LIFE   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bayesian; Fat tissue perfusion; Intraindividual variability; Markov chain Monte Carlo; PBPK; Physiologically based modeling; Population modeling; Styrene; Uncertainty

Indexed keywords

CARCINOGEN; STYRENE; STYRENE OXIDE;

ARTICLE; BAYES THEOREM; CALIBRATION; EXERCISE; HUMAN; INHALATION; METABOLIC CAPACITY; METABOLISM; MONTE CARLO METHOD; NEUROTOXICITY; OBSERVER VARIATION; PARTITION COEFFICIENT; POPULATION MODEL; PROBABILITY; RELIABILITY; TOXICOKINETICS; VALIDATION PROCESS;

ANIMALIA;

EID: 0037082621     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.2001.9331     Document Type: Article

References (74)

1. Effect of physical exercise on uptake, distribution and elimination of vapors in man
2. Toluene exposure I. Concentration in alveolar air and blood at rest during exposure
3. Exposure to styrene I. Concentration in alveolar air and blood at rest and during exercise and metabolism
4. Exposure to methylene chloride I. Its concentration in alveolar air and blood at rest and exercise and its metabolism
5. Hepatic elimination of flowing substrates: The distributed model
6. Lean body mass: Its clinical significance and estimation from excess fat and total body water determinations
7. Statistical issues in toxicokinetic modeling: A Bayesian perspective
8. Bayesian methods in health-related research
9. Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics
10. Statistical analysis of Fisher et al. PBPK model of trichloroethylene kinetics
11. Applications of population approaches in toxicology
12. Population toxicokinetics of tetrachloroethylene
13. Population toxicokinetics of benzene
14. MCSim: A Monte Carlo simulation program
15. Physiological parameter values for physiologically based pharmacokinetic models
16. Adipose tissue blood flow during prolonged exercise II
17. A physiological model for tert-amyl methyl ether and tert-amyl alcohol: Hypothesis testing of model structures
18. Tissue weights and rates of blood flow in man for predictions of anaesthetic uptake and distribution
19. A physiologic pharmacokinetic model for styrene and styrene-7,8-oxide in mouse, rat and man
20. Quantification of biological variability
21. Human styrene exposure. V. Development of a model for biological monitoring
22. Variability in biological monitoring of solvent exposure. I. Development of a population physiological model
23. Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans
24. Uptake, distribution and elimination of styrene in man: Concentration in subcutaneous tissue
25. Density of body fat in man and other animals
26. Inhalation anesthesia using physiologically based pharmacokinetic models
27. Extrapolation of physiological parameters for physiologically based simulation models
28. Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues
29. Physiological pharmacokinetic analysis using population modeling and informative prior distribution
30. Inference from iterative simulation using multiple sequences
31. A physiologically based pharmacokinetic model for methyl mercury in the pregnant rat and fetus
32. Sensitivity analysis for physiologically based pharmacokinetic models§
33. Styrene
34. Styrene-7,8-oxide
35. Ethnic differences in biological monitoring of several organic solvents II. A simulation study with a physiologically based pharmacokinetic model
36. Modelling of respiratory exchange of polar solvents
37. Experimental data from closed chamber gas uptake studies suggest lower uptake rate of chemical than calculated from literature values on alveolar ventilation
38. Development of a new technique for risk assessment using physologically based toxicokinetic models
39. Spreadsheet programming: A new approach in physiologically based modeling of solvent toxicokinetics
40. Nonlinearity detection: Advantages of nonlinear mixed-effects modeling
41. Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects
42. Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise
43. A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane
44. Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene
45. A compartmental model for the kinetics of mercury vapor in humans
46. Quantitative evaluation of alternative mechanisms of blood disposition of di(n-butyl) phthalate and mono(n-butyl) phthalate in rats
47. Evaluation of biologically based dose-response modeling for developmental toxicity: A workshop report
48. Use of physiologically based pharmacokinetic models to establish biological exposure indices
49. Dose-dependent kinetics of inhaled styrene in man
50. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects
51. In vitro kinetics of styrene and styrene oxide metabolism in rat, mouse, and human
52. Relationship of subcutaneous adipose tissue blood flow to thickness of subcutaneous tissue and total body fat mass
53. Sources of variation in 133Xenon washout after subcutaneous injection on the abdomen
54. Implementation of EPA revised cancer assessment guidelines: Incorporation of mechanistic and pharmacokinetic data
55. Retention of styrene following controlled exposure to constant and fluctuating air concentrations
56. Modeling the acute neurotoxicity of styrene
57. A population physiologically based pharmacokinetic/pharmacodynamic model for the inhibition of 11-β-hydroxysteroid dehydrogenase activity by glycyrrhetic acid
58. Population models
59. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans
60. Bayesian population pharmacokinetic and pharmacokinetic analyses using mixture models
61. Inhalation toxicokinetics of styrene in rat and mouse
62. The population approach to pharmacokinetic data analysis: Rationale and standard data analysis methods
63. Population pharmacokinetics/pharmacodynamics
64. Bayesian computational methods
65. Parameter variability and the interpretation of physiologically based pharmacokinetic modeling results
66. Incorporating Monte Carlo simulation into physiologically based pharmacokinetic models using Advanced Continuous Simulation Language (ACSL): A computational method
67. Bayesian nonparametric population models: Formulation and comparison with likelihood approaches
68. Bayesian analysis of linear and non-linear population models by using the Gibbs sampler
69. Total body water volumes for adult males and females estimated from simple anthropometric measurements
70. Chemical analyses of the body
71. Reference values for resting blood flow to organs of man
72. Optimization issues in physiological toxicokinetic modeling: A case study with benzene
73. Population pharmacokinetic/pharmacodynamic methodology and applications: A bibliography